Sino Biopharmaceutical Limited
1177
Classifica tra le azioni
#1766
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Prezzo delle azioni
$0.68180748
Capitalizzazione di mercato
$12.14B
Variazione (1 giorno)
-1.30%
Variazione (1 anno)
-28.39%
Paese
HK
Scambia Sino Biopharmaceutical Limited (1177)
Categoria
Healthcare
Ricavi di Sino Biopharmaceutical Limited (1177)
Ricavi nel Jun 2026 TTM: $4.88B
Secondo gli ultimi rapporti finanziari di Sino Biopharmaceutical Limited, i ricavi attuali dell'azienda (TTM) sono pari a $4.88B. Nel 2023, l'azienda ha registrato ricavi di $3.70B una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $3.77B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Sino Biopharmaceutical Limited da 2000 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $4.88B | 23.50% |
| 2024 | $3.95B | 6.85% |
| 2023 | $3.70B | -1.90% |
| 2022 | $3.77B | -10.72% |
| 2021 | $4.23B | 16.75% |
| 2020 | $3.62B | 4.01% |
| 2019 | $3.48B | 14.60% |
| 2018 | $3.04B | 33.32% |
| 2017 | $2.28B | 11.60% |
| 2016 | $2.04B | 8.78% |
| 2015 | $1.88B | 17.41% |
| 2014 | $1.60B | 25.29% |
| 2013 | $1.28B | 18.63% |
| 2012 | $1.08B | 44.84% |
| 2011 | $742.34M | 40.70% |
| 2010 | $527.59M | 26.12% |
| 2009 | $418.31M | 42.04% |
| 2008 | $294.49M | 97.15% |
| 2007 | $149.37M | 58.30% |
| 2006 | $94.36M | -3.22% |
| 2005 | $97.50M | -27.90% |
| 2004 | $135.23M | 27.73% |
| 2003 | $105.87M | 19.26% |
| 2002 | $88.77M | 28.20% |
| 2001 | $69.24M | 37.37% |
| 2000 | $50.40M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $2.54B | -48.08% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | -82.99% |
US
|
|
| - | - |
IT
|
